Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.
Mosaei, H., Molodtsov, V., Kepplinger, B., Harbottle, J., Moon, C.W., Jeeves, R.E., Ceccaroni, L., Shin, Y., Morton-Laing, S., Marrs, E.C.L., Wills, C., Clegg, W., Yuzenkova, Y., Perry, J.D., Bacon, J., Errington, J., Allenby, N.E.E., Hall, M.J., Murakami, K.S., Zenkin, N.(2018) Mol Cell 72: 263-274.e5
- PubMed: 30244835 
- DOI: https://doi.org/10.1016/j.molcel.2018.08.028
- Primary Citation of Related Structures:  
6CUU, 6CUX - PubMed Abstract: 
Antibiotic-resistant bacterial pathogens pose an urgent healthcare threat, prompting a demand for new medicines. We report the mode of action of the natural ansamycin antibiotic kanglemycin A (KglA). KglA binds bacterial RNA polymerase at the rifampicin-binding pocket but maintains potency against RNA polymerases containing rifampicin-resistant mutations ...